ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
48 announcements with these filters
Onesource Specialty Pharma Limited has allotted 900 equity shares under its Employee Stock Option Plan. This allotment updates the company's total paid-up share capital.
OneSource Specialty Pharma allotted 900 shares under its ESOP 2021 scheme at an exercise price of ₹278 per share, totaling ₹0.03 Crore.
Onesource Specialty Pharma Limited appointed B S R & Co LLP as its Statutory Auditor for a 60-month term, effective September 23, 2026.
OneSource Specialty Pharma Ltd appointed M/s B S R & Co LLP as its Statutory Auditors for a five-year term ending at the 24th AGM.
OneSource Specialty Pharma held its 19th Annual General Meeting on September 23, 2026. Shareholders transacted ordinary and special business items, including re-appointments and related party approvals.
OneSource Specialty Pharma issued an addendum to its 19th AGM notice regarding additional disclosures for agenda items about material related party transactions.
OneSource reported strong Q1 FY27 results with Revenue of INR 4,490M (up 37% YoY) and EBITDA of INR 1,233M (up 39% YoY), driven by semaglutide commercialization and biologics expansion.
OneSource Specialty Pharma Limited has submitted its Business Responsibility & Sustainability Report for the financial year ended March 31, 2026, as required by regulation.
OneSource Specialty Pharma Limited has released its Integrated Annual Report for FY 2025-26 and scheduled its 19th AGM for September 23, 2026.
Onesource Specialty Pharma has issued a notice for its 19th Annual General Meeting scheduled for September 23, 2026. The meeting will address financial statements and director appointments.
India Ratings has upgraded OneSource Specialty Pharma Limited's long-term credit rating to 'IND A' with a Positive outlook. Short-term ratings were affirmed at 'IND A1'.
Management is aggressively optimistic, leveraging the GLP-1 (Semaglutide) boom to mask temporary supply disruptions. Strategic shift toward CDMO for Softgel and Biologics aims to diversify beyond traditional captive manufacturing.
Onesource Specialty Pharma Limited allotted equity shares under its Employee Stock Option Plan. This issuance increases the company's total paid-up share capital.
Onesource Specialty Pharma allotted 2,900 equity shares under its ESOP 2021 scheme. The exercise price for these shares was ₹278 per share.
OneSource Specialty Pharma reported strong Q1FY27 results, with revenue growing 37% YoY and EBITDA increasing 39% YoY, driven by semaglutide commercialization and new customer wins.
OneSource Specialty Pharma announced Preeti Kalra as a new Senior Management Personnel, while Ravi Kumar has resigned from his SMP position effective July 24, 2026.
OneSource Specialty Pharma Ltd reported revenue from operations of ₹449 Cr (+37.2% YoY) and net profit of ₹25 Cr for Q1 FY27.
Onesource Specialty Pharma Ltd has submitted its quarterly shareholding pattern for the quarter ended June 30, 2026. This filing provides details on the company's equity ownership distribution.
OneSource Specialty Pharma Limited has scheduled a board meeting for July 24, 2026, to approve the company's unaudited financial results for the quarter ended June 30, 2026.
OneSource Specialty Pharma announced a strategic manufacturing partnership with Formycon AG. OneSource will provide integrated biologics manufacturing from its Bangalore facility for global markets.
OneSource informs that DRL’s supply delay of Semaglutide has no material impact. The company cites other demand and upcoming capacity additions.
Onesource Specialty Pharma allotted 24,190 equity shares under its ESOP scheme. Total paid-up capital increased to 11,46,69,991 shares following the allotment.
OneSource Specialty Pharma allotted 24,190 equity shares under its ESOP scheme. This allotment increased the total paid-up share capital to ₹11.47 Crore.
OneSource Specialty Pharma allotted 24,190 equity shares under its 2021 ESOP plan. The exercise price of INR 278 per share results in a 0.67 Crore transaction.
OneSource Specialty Pharma disclosed a routine US‑FDA cGMP inspection at its Sterile Product Division in Bengaluru, concluded with one observation. The company will address the observation promptly.
Q4 FY26 marked a strong recovery with 47% sequential revenue growth to US$48M, driven by Semaglutide launches and drug-device combinations.
OneSource Specialty Pharma Limited reported audited annual standalone and consolidated financial results for FY26. The filing provides comprehensive revenue, profit, and asset visibility for investors.
Prateek Gupta resigned as Senior Vice President and Head – Technical Development. He was relieved from OneSource Specialty Pharma effective May 15, 2026.
OneSource Specialty Pharma received Karnataka government approval for its Unit II capacity expansion. This strategic move aims to enhance manufacturing capabilities to service global partners.
OneSource Specialty Pharma received Karnataka government approval for its Unit II expansion project. The facility expansion enhances manufacturing capacities to service global partners and support growth.